Patents by Inventor Richard Harkins

Richard Harkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody Mimetic Scaffolds
    Publication number: 20120302492
    Abstract: Provided herein are protein scaffolds, e.g. antibody mimetic scaffolds, comprising a three finger protein domain that specifically bind to target molecules, polynucleotides encoding such proteins, methods of using such proteins, and libraries of such scaffolds.
    Type: Application
    Filed: November 1, 2010
    Publication date: November 29, 2012
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Richard Harkins, Fang Jin, Ye Jin, Marian Seto
  • Factor VIII Muteins with Reduced Immonugenicity
    Publication number: 20110112022
    Abstract: The invention relates to modified Factor VIII molecules with reduced N-linked glycosylation and reduced immunogenicity. The invention also relates to methods of using modified Factor VIII molecules, for example, to treat patients afflicted with hemophilia.
    Type: Application
    Filed: June 25, 2009
    Publication date: May 12, 2011
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Fred Jullien Aswad, Richard Harkins, Hsiao-Lai Liu, John E. Murphy, Faye Wu, Ying Zhu
  • Isolated human antibodies that bind epitopes on RG1
    Patent number: 7893217
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 22, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Methods for treating disease-states associated with RG1 using immunoconjugates
    Patent number: 7887804
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: February 15, 2011
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • RG1 ANTIBODIES AND USES THEREOF
    Publication number: 20100081795
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: September 15, 2009
    Publication date: April 1, 2010
    Applicant: Bayer Schering Pharma
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090292112
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: November 26, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • RG1 antibodies and uses thereof
    Patent number: 7611706
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 3, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • RG1 antibodies and uses thereof
    Patent number: 7608263
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: October 27, 2009
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20090214422
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: August 27, 2009
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • RG1 antibodies and uses thereof
    Publication number: 20080226656
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: September 18, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • RG1 antibodies and uses thereof
    Publication number: 20080138899
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 12, 2008
    Applicant: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • Interferon-beta gene therapy using an improved, regulated expression system
    Publication number: 20080076729
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: April 4, 2007
    Publication date: March 27, 2008
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Paul Szymanski
  • RG1 antibodies and uses thereof
    Patent number: 7335748
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: February 26, 2008
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Patent number: 7307154
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: December 11, 2007
    Assignee: Bayer Schering Pharma Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
    Publication number: 20070179113
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: April 4, 2007
    Publication date: August 2, 2007
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Harald Petry, Paul Szymanski
  • Interferon-beta gene therapy using an improved, regulated expression system
    Publication number: 20060292609
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 28, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Paul Szymanski
  • Treatment of disease using an improved regulated expression system
    Publication number: 20060281703
    Abstract: The present invention provides an improved, expression system for the regulated expression of an encoded protein or nucleic acid therapeutic molecule in the cells of a subject, for use in the treatment of disease. In particular, the present invention provides an improved, regulated gene expression system, and pharmaceutical compositions and uses thereof for treatment of disease.
    Type: Application
    Filed: May 18, 2006
    Publication date: December 14, 2006
    Applicant: Schering Aktiengesellschaft
    Inventors: Maxine Bauzon, Richard Harkins, Terry Hermiston, Peter Kretschmer, Paul Szymanski
  • RG1 antibodies and uses thereof
    Publication number: 20050019845
    Abstract: The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.
    Type: Application
    Filed: July 20, 2004
    Publication date: January 27, 2005
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas Schneider
  • DNA encoding a novel RG1 polypeptide
    Publication number: 20040152139
    Abstract: The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.
    Type: Application
    Filed: July 22, 2003
    Publication date: August 5, 2004
    Applicant: Schering Aktiengesellschaft
    Inventors: Richard Harkins, Deborah Parkes, Gordon Parry, Renate Parry, Douglas W. Schneider
  • Tool stand
    Patent number: D747167
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: January 12, 2016
    Inventor: Richard A. Harkin